Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Jerusalem Daily Journal.
Press releases published on May 5, 2025
סקוורטולק משיקה פלטפורמת מוקדים טלפוניים חדשה - הצעד הראשון בחזון הנועז לאוטומציית מכירות
EIN Presswire
·
May 5, 2025
ספק פתרונות תקשורת בענן בעל הדירוג הגבוה ביותר, משיק תוכנה חדשה שמשנה את הדרך שבה צוותי מכירות יוצרים קשר עם לידים, ממירים אותם ללקוחות וצומחים JERUSALEM, ISRAEL, May 5, 2025 /EINPresswire.com/ -- סקוורטולק, פתרון למוקדים מבוסס ענן שנבנה במיוחד עבור …
Kornit Digital and Gooten Expand Access to Kornit’s Global Fulfillment Network for On-Demand Production
GlobeNewswire
·
May 5, 2025
ROSH-HA`AYIN, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Kornit Digital LTD. (NASDAQ: KRNT) (“Kornit” or the “Company”), a global leader in sustainable, on-demand digital fashion and textile production technologies, today announced that Gooten, a leading …
MediWound to Report First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on …
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
GlobeNewswire
·
May 5, 2025
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that …
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®
GlobeNewswire
·
May 5, 2025
Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ Transplantation A Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as …
Solargik launches SOMA Pro, the next generation of its AI-powered platform for intelligent solar tracking, diagnostics, and control at Intersolar 2025
GlobeNewswire
·
May 5, 2025
SOMA Pro is a fully integrated software and hardware system that delivers real-time visibility and full remote control. AI-driven optimization: Proprietary algorithms increase yield and proactively prevent losses. Ground-truth loss attribution: In-house …